New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

As more people take GLP-1 medications for ... is thanks in part to so many people taking drugs like Ozempic and Wegovy for weight loss. “If I have six patients in a day, at least two of them ...

Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases, ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

As broader approval for GLP-1 weight loss drugs spurs higher demand, it’s also causing employer drug spending to spike.

Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like ...